The US has bought up virtually all the stocks for the next three months of one of the two drugs proven to work against Covid-19, leaving none for the UK, Europe or most of the rest of the world.
The drug, which was invented for Ebola but failed to work, is under patent to California-based Gilead, which means no other company in wealthy countries can make it. The cost is around $3,200 per treatment of six doses, according to the US government statement.
Dr Andrew Hill, senior visiting research fellow at Liverpool University said there was a way for the UK to secure supplies of this and other drugs during the pandemic, through what is known as a compulsory licence, which overrides the intellectual property rights of the company. That would allow the UK government to buy from generic companies in Bangladesh or India, where Gilead’s patent is not recognised.